GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EirGenix Inc (ROCO:6589) » Definitions » Additional Paid-In Capital

EirGenix (ROCO:6589) Additional Paid-In Capital : NT$6,953 Mil(As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is EirGenix Additional Paid-In Capital?


EirGenix's quarterly additional paid-in capital increased from Dec. 2023 (NT$7,830 Mil) to Mar. 2024 (NT$7,851 Mil) but then stayed the same from Mar. 2024 (NT$7,851 Mil) to Jun. 2024 (NT$6,953 Mil).

EirGenix's annual additional paid-in capital declined from Dec. 2021 (NT$10,476 Mil) to Dec. 2022 (NT$7,734 Mil) but then increased from Dec. 2022 (NT$7,734 Mil) to Dec. 2023 (NT$7,830 Mil).


EirGenix Additional Paid-In Capital Historical Data

The historical data trend for EirGenix's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EirGenix Additional Paid-In Capital Chart

EirGenix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,055.78 2,813.97 10,475.95 7,734.14 7,830.22

EirGenix Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,675.83 7,700.10 7,830.22 7,850.71 6,953.37

EirGenix Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

EirGenix Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of EirGenix's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


EirGenix Business Description

Industry
Traded in Other Exchanges
N/A
Address
No. 101, Lane 169, Kangning Street, Xizhi District, New Taipei, TWN, 22180
EirGenix Inc is engaged in biosimilar and new drug research and development as well as biopharmaceutical contract development and manufacturing services, including cell line construction platforms, process development platforms, analytical science and protein characterisation, as well as PIC/S facilities to provide clinical trial drug production. Its services include Cell Line Development, Process Development, Analytical Science and Quality Control, cGMP manufacturing-mammalian system, cGMP manufacturing-microbial system, and Antibody Drug Conjugate.

EirGenix Headlines

No Headlines